Radiolabelled antibody fragments for use in treating cancer

US11298433B2 · kind B2 · utility

Assignee

• VRIJE UNIVERSITEIT BRUSSEL · BE

Inventors

• Tony Lahoutte · Ganshoren, BE
• Matthias D'Huyvetter · Ekeren, BE
• Jens De Vos · Strombeek-Bever, BE
• Nick Devoogdt · Zemst, BE

Key dates

• Filing date: Jul 15, 2016
• Grant date: Apr 12, 2022
• Expiry date: Oct 12, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/569
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are methods, kits, and compositions for stratifying and treating subjects, e.g., subjects having cancer. In some examples, the methods involve use of a radiolabelled heavy chain variable domain derived from a heavy chain antibody (VHH), or a functional fragment thereof, as both a screening agent and a treatment agent. In some examples, the VHH, or a functional fragment thereof, that is radiolabelled with a radioisotope that is both a γ-emitter and β-emitter.